Meno Formula
Natural health product licensed in Canada
- Other names
- MenoVantage PE
- Licence holder
- Bioclinic Naturals Inc.
- NPN or DIN-HM
- 80041163
- Status
- Active licence
- Licence date
- 20 March 2013
- Revision date
- 4 June 2026
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| (2S)-7-[[6-O-(6-Déoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-méthoxyphényl)-4H-1-benzopyrane-4-one Source : Hespéridine | 30 mg | Not calculated |
| (2S)-7-[[6-O-(6-Déoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-méthoxyphényl)-4H-1-benzopyrane-4-one Source : Fruit | 30 mg | Not calculated |
| (2S)-7-[[6-O-(6-Déoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-méthoxyphényl)-4H-1-benzopyrane-4-one Source : Citrus sinensis | 30 mg | Not calculated |
| Gamma-oryzanol Source : Oryza sativa - seed bran | 75 mg | Not calculated |
| Gamma-oryzanol Source : Gamma-oryzanol | 75 mg | Not calculated |
| Actaea racemosa Source : Racine et rhizome Extract : Extract Type TBA Extraction ratio : 9:1 Dry plant equivalent : 720 mg Potency : 2.5 % Triterpene glycosides | 80 mg | Not calculated |
Non-medicinal ingredients
Eau purifiée, Silice, Phosphate de dicalcium dihydraté, NA, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Capsule | 2 Tous les jours |
Uses authorised in Canada
For the reduction of hot flashes, night sweats and other symptoms of menopause.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
n/a.
Source
Official Health Canada record, licence 80041163
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.